

Estimated New Cancer Deaths
By Gender for all Sites and
for Gastrointestinal Organs
2022/USA

	Estimated New Cases			Estimated New Deaths		
	Total	Male	Female	Total	Male	Female
All Sites	1,918,030	983,160	934,870	609,360	322,090	287,270
Digestive System	343,040	193,350	149,690	171,920	99,940	71,980
Esophagus	20,640	16,510	4,130	16,410	13,250	3,160
Stomach	26,380	15,900	10,480	11,090	6,690	4,400
Small Intestine	11,790	6,290	5,500	1,960	1,110	850
Colon*	151,030	80,690	70,340	52,580	28,400	24,180
Rectum	44,850	26,650	18,200			
Anus, Anal Canal & Anorectum	9,440	3,150	6,290	1,670	740	930
Liver & Intrahepatic Bile Duct	41,260	28,600	12,660	30,520	20,420	10,100
Gallbladder & other biliary	12,130	5,710	6,420	4,400	1,830	2,570
Pancreas	62,210	32,970	29,240	49,830	25,970	23,860
Other Digestive Organs	8,160	3,530	4,630	3,460	1,530	1,930

*Deaths for colon & rectum cancers are combined because of a large number of deaths from rectal cancer misclassified as colon.
American Cancer Society Statistics

I enclose my donation of _____ dollars for FARGO. (Pls. make cheque payable to FARGO)

Name: _____

Address: _____

Phone #: _____

Fax #: _____

E-mail: _____


Signature: _____

Dr. Paul H. Sugarbaker
Foundation for Applied Research
in Gastrointestinal Oncology
3629 Fulton St. NW
Washington, DC 20007

* IRS Section 501(c)(3) exempt private foundation

*FARGO Tax Identification No. 52-1797893

FARGO



**Foundation for Applied
Research in
Gastrointestinal Oncology**

Dr. Paul H. Sugarbaker
Foundation for Applied Research
in Gastrointestinal Oncology
3629 Fulton St. NW
Washington, DC 20007

The FARGO Mission

1. To maintain and enhance a multidisciplinary approach to the treatment of gastrointestinal cancer. This includes the prevention and treatment of carcinomatosis and sarcomatosis. The proper combinations of surgery, intraperitoneal chemotherapy, intravenous chemotherapy, radiation therapy, and hyperthermia are a priority for these efforts. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are being optimized!
2. To provide monetary support for an international program in gastrointestinal oncology. FARGO is a major supporter of the educational initiatives of the Peritoneal Surface Oncology Group International (PSOGI).
3. To provide the general public with information about the needs of patients with gastrointestinal cancer. Treatment failure with primary disease can be prevented. Metastases can be cured. Select the proper treatment to get good results.
4. To provide the general public with information about the needs for clinical and basic science research in gastrointestinal cancer. To emphasize the pressing need for cytoreductive surgical expertise in the management of peritoneal metastases.
5. To provide international meetings for clinicians and researchers wishing to prevent and improve the treatment of gastrointestinal cancer. The outreach is global.

Foundation for Applied Research in Gastrointestinal Oncology

Paul H. Sugarbaker, M.D.
Foundation for Applied Research
in Gastrointestinal Oncology

3629 Fulton St. NW
Washington, DC 20007

Tel #: 202-844-6061

Fax #: 202-844-2552

E-mail: Paul.Sugarbaker@outlook.com

The Foundation for Applied Research in Gastrointestinal Oncology (FARGO) is a unique organization with a well-defined mission. We are pledged to promote clinical and laboratory research in gastrointestinal cancer, especially the cure of peritoneal metastases. Research in the peritoneal spread of gastrointestinal cancer has been neglected in the past because of the lack of progress in this field. Recent breakthroughs suggest that rapid advancement can be achieved with innovative research efforts. CRS works! HIPEC works!

FARGO is a not-for-profit organization with clinical research facilities located at 3629 Fulton St. NW, Washington, DC. As a not-for-profit organization we rely on the generosity of corporate, foundation and individual donors to further our research.

For information about gastrointestinal cancer, FARGO and how you can support this vital research, please call (202) 844-6061.